Exblifep (cefepime-enmetazobactam) meets pre-specified primary endpoints in Phase III ALLIUM clinical trial in complicated urinary tract infections

In RCT (n=1034) of this combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and 4th generation cephalosporin, cefepime, overall success (clinical cure /microbiological eradication at test of cure visit) was 79.1vs. 58.9% for piperacillin-tazobactam.

Biospace Inc.